These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 16573787)
1. Systematic review: the use of mesalazine in inflammatory bowel disease. Bergman R; Parkes M Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787 [TBL] [Abstract][Full Text] [Related]
2. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Prakash A; Markham A Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690 [TBL] [Abstract][Full Text] [Related]
3. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Clemett D; Markham A Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042 [TBL] [Abstract][Full Text] [Related]
4. A practical guide to the management of distal ulcerative colitis. Ardizzone S; Bianchi Porro G Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342 [TBL] [Abstract][Full Text] [Related]
5. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
6. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Schroeder KW Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503 [TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356 [TBL] [Abstract][Full Text] [Related]
8. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Hanauer SB Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743 [TBL] [Abstract][Full Text] [Related]
9. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445 [TBL] [Abstract][Full Text] [Related]
10. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. Thomson AB Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778 [TBL] [Abstract][Full Text] [Related]
11. Mesalazine for the treatment of inflammatory bowel disease. Criscuoli V; Modesto I; Orlando A; Cottone M Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798 [TBL] [Abstract][Full Text] [Related]
12. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971 [TBL] [Abstract][Full Text] [Related]
13. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Safdi AV; Cohen RD Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732 [TBL] [Abstract][Full Text] [Related]
14. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Mulder CJ; van den Hazel SJ Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596 [TBL] [Abstract][Full Text] [Related]